12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CK-2127107: Phase I started

Cytokinetics began a double-blind, placebo-controlled, crossover Phase I trial to evaluate single ascending-doses of oral CK-2127107 in...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >